
    
      This is a single center, randomized, double-blind, placebo-controlled, single dose escalation
      phase 1 study. The objective of this study is to evaluate the safety, tolerability,
      pharmacokinetics and pharmacodynamics of subcutaneous administered SHR-1819 in healthy
      subjects.
    
  